Cargando…
(18)F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma
PURPOSE: Accurate prognostic markers are urgently needed to identify diffuse large B-Cell lymphoma (DLBCL) patients at high risk of progression or relapse. Our purpose was to investigate the potential added value of baseline radiomics features to the international prognostic index (IPI) in predictin...
Autores principales: | Eertink, Jakoba J., van de Brug, Tim, Wiegers, Sanne E., Zwezerijnen, Gerben J. C., Pfaehler, Elisabeth A. G., Lugtenburg, Pieternella J., van der Holt, Bronno, de Vet, Henrica C. W., Hoekstra, Otto S., Boellaard, Ronald, Zijlstra, Josée M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803694/ https://www.ncbi.nlm.nih.gov/pubmed/34405277 http://dx.doi.org/10.1007/s00259-021-05480-3 |
Ejemplares similares
-
Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features
por: Eertink, Jakoba J., et al.
Publicado: (2022) -
Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor
por: Zwezerijnen, Gerben J. C., et al.
Publicado: (2022) -
An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients
por: Ferrández, Maria C., et al.
Publicado: (2023) -
Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma
por: Eertink, Jakoba J., et al.
Publicado: (2022) -
External validation: a simulation study to compare cross-validation versus holdout or external testing to assess the performance of clinical prediction models using PET data from DLBCL patients
por: Eertink, Jakoba J., et al.
Publicado: (2022)